Skip to content

SNY

Sanofi

NASDAQ · Healthcare · Drug Manufacturers - General · FR

$47.29
+4.32%
Ask drillr

Year over year

Reported trailing growth

Revenue
+21.0%
EBITDA
+44.1%
EBIT
+5.3%
EPS
-84.7%
Free cash flow
+51.7%
Operating cash flow
+107.6%

Forward estimates

Based on analyst estimates

Revenue
-54.9%
EBITDA
-30.6%
EPS
+222.5%

Three-year CAGR

Revenue
+4.8%
EBITDA
-2.6%
EBIT
-1.9%
Net income
-2.3%
EPS
+0.1%
Free cash flow
+6.4%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026